Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017

Geneviève I C G Ector^{1

2}, Otto Visser³, Peter E Westerweel⁴, Jeroen J W M Janssen⁵, Nicole M A Blijlevens⁶, Avinash G Dinmohamed^{5

7

8

9}

Affiliations

¹ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. genevieve.ector@radboudumc.nl.
² Department of Hematology, Radboud IKNL, Department Research and Development, Nijmegen, The Netherlands. genevieve.ector@radboudumc.nl.
³ Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁴ Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
⁵ Department of Hematology, Cancer Center Amsterdam, Amsterdam University medical centers, location VUmc, Amsterdam, The Netherlands.
⁶ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁸ Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.
⁹ Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.

Geneviève I C G Ector et al. Leukemia. 2020 Dec.

. 2020 Dec;34(12):3408-3412.

doi: 10.1038/s41375-020-0902-1. Epub 2020 Jun 8.

Geneviève I C G Ector^{1

2}, Otto Visser³, Peter E Westerweel⁴, Jeroen J W M Janssen⁵, Nicole M A Blijlevens⁶, Avinash G Dinmohamed^{5

7

8

9}

¹ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. genevieve.ector@radboudumc.nl.
² Department of Hematology, Radboud IKNL, Department Research and Development, Nijmegen, The Netherlands. genevieve.ector@radboudumc.nl.
³ Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁴ Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
⁵ Department of Hematology, Cancer Center Amsterdam, Amsterdam University medical centers, location VUmc, Amsterdam, The Netherlands.
⁶ Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
⁸ Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.
⁹ Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.

Erratum in

Correction: Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.
Ector GICG, Visser O, Westerweel PE, Janssen JJWM, Blijlevens NMA, Dinmohamed AG. Ector GICG, et al. Leukemia. 2020 Dec;34(12):3440. doi: 10.1038/s41375-020-01040-0. Leukemia. 2020. PMID: 32989222

No abstract available

1. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2008;23:602–4. - DOI
1. Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century. Eur J Haematol. 2015;94:540–5. - DOI
1. Krok-Schoen JL, Fisher JL, Stephens JA, Mims A, Ayyappan S, Woyach JA, et al. Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer Med. 2018;7:3425–33. - DOI
1. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185–92. - DOI
1. Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52:837–41. - DOI